Menu
Recruiting NCT06259162

LAG3 Expression in Triple Negative Breast Cancer

No phase Interventional Triple Negative Breast Cancer Immune Checkpoint Inhibitor

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: LAG-3 expression / immune checkpoint protein expression.
Who it may be relevant to
Registry conditions: Triple Negative Breast Cancer, Immune Checkpoint Inhibitor. Basic parameters: No limits · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
South Korea
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

The Evaluation the Relationship Between LAG-3 Expression / Immune Checkpoint Protein Expression and Neoadjuvant Chemotherapy Plus Immune Checkpoint Inhibitor in Triple Negative Breast Cancer

Overview

This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.

Interventions

  • Procedure LAG-3 expression / immune checkpoint protein expression
    Evaluate the tissue and blood before and after chemotherapy

Primary outcome measures

  • LAG-3 expression/immune checkpoint preotein expression [Time frame: Before chemotherapy, 1 weeks & 3 weeks after chemotherapy, curative surgery]

Eligibility criteria

Inclusion criteria

  • Planned neoadjuvant chemotherapy
  • Triple negative breast cancer

Exclusion criteria

  • HER2-positive breast cancer
  • Hormone receptor positive breast cancer

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Screening

Study locations

South Korea · 1 center
  • Ji-Yeon Kim — Seoul

Identifiers

NCT: NCT06259162 · LAG3_Breast

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗